Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ibrexafungerp for Recurrent Vulvovaginal Candidiasis
NCT04029116Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of ibrexafungerp in recurrent vulvovaginal candidiasis (RVVC), sponsored by SCYNEXIS, Inc.. Started Oct 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT04029116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029116.